Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
March 10 2014 - 4:00PM
Marketwired
Dynavax Reports Fourth Quarter and Year End 2013 Financial Results
BERKELEY, CA--(Marketwired - Mar 10, 2014) - Dynavax
Technologies Corporation (NASDAQ: DVAX) today reported financial
results for the fourth quarter and year ended December 31, 2013.
The Company had $189.4 million in cash, cash equivalents and
marketable securities as of December 31, 2013.
For the quarter ended December 31, 2013, Dynavax reported total
revenues of $2.8 million compared to $1.8 million for the fourth
quarter of 2012. For the year ended December 31, 2013, total
revenues were $11.3 million compared to $9.7 million for
2012.
General and administrative expenses were $3.7 million for the
quarter ended December 31, 2013 compared to $9.3 million for the
fourth quarter of 2012. For the twelve months ended December 31,
2013, general and administrative expenses were $25.9 million
compared to $28.2 million for the same period in 2012. The 2013
twelve month period includes non-recurring and non-cash stock-based
severance costs of $7.7 million compared to $2.1 million for the
same period in 2012. General and administrative expenses other than
these organizational transition costs decreased by 38% during the
fourth quarter and 28% for the twelve month period of
2013.
Research and development expenses were $12.1 million for the
quarter ended December 31, 2013 compared to $12.5 million for the
fourth quarter of 2012. For the twelve months ended December 31,
2013, research and development expenses were $50.9 million compared
to $49.1 million for the same period in 2012.
The net loss allocable to common stockholders for the twelve
months ended December 31, 2013 was $75.2 million, or $0.38 per
basic and diluted share, which includes a one-time non-cash deemed
dividend of $8.5 million related to the beneficial conversion
feature of the Series B Convertible Preferred Stock. The net loss
allocable to common stockholders for the twelve months ended
December 31, 2012 was $69.9 million, or $0.41 per basic and diluted
share.
About HEPLISAV™
HEPLISAV is an investigational adult hepatitis B vaccine that
combines hepatitis B surface antigen with a proprietary Toll-like
Receptor 9 agonist to enhance the immune response. Dynavax has
worldwide commercial rights to HEPLISAV.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers
and develops novel vaccines and therapeutics in the areas of
infectious and inflammatory diseases and oncology. Dynavax's lead
product candidate is HEPLISAV, a Phase 3 investigational adult
hepatitis B vaccine. For more information visit
www.dynavax.com.
|
DYNAVAX TECHNOLOGIES CORPORATION |
CONSOLIDATED STATEMENTS OF OPERATIONS |
(In thousands, except per share amounts) |
(Unaudited) |
|
|
|
Three Months Ended December 31, |
|
|
Years Ended December 31, |
|
|
|
2013 |
|
|
2012 |
|
|
2013 |
|
|
2012 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration revenue |
|
$ |
1,580 |
|
|
$ |
1,008 |
|
|
$ |
4,929 |
|
|
$ |
4,610 |
|
|
Grant
revenue |
|
|
1,283 |
|
|
|
751 |
|
|
|
5,138 |
|
|
|
3,939 |
|
|
Service and license revenue |
|
|
(16 |
) |
|
|
47 |
|
|
|
1,184 |
|
|
|
1,165 |
|
Total revenues |
|
|
2,847 |
|
|
|
1,806 |
|
|
|
11,251 |
|
|
|
9,714 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
12,131 |
|
|
|
12,515 |
|
|
|
50,870 |
|
|
|
49,146 |
|
|
General and administrative |
|
|
3,700 |
|
|
|
9,293 |
|
|
|
25,943 |
|
|
|
28,164 |
|
|
Unoccupied facility expense |
|
|
8 |
|
|
|
-- |
|
|
|
926 |
|
|
|
-- |
|
Total operating expenses |
|
|
15,839 |
|
|
|
21,808 |
|
|
|
77,739 |
|
|
|
77,310 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(12,992 |
) |
|
|
(20,002 |
) |
|
|
(66,488 |
) |
|
|
(67,596 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
(47 |
) |
|
|
83 |
|
|
|
116 |
|
|
|
291 |
|
Interest expense |
|
|
83 |
|
|
|
(586 |
) |
|
|
-- |
|
|
|
(2,351 |
) |
Other income (expense) |
|
|
(100 |
) |
|
|
(38 |
) |
|
|
(348 |
) |
|
|
(293 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
(13,056 |
) |
|
|
(20,543 |
) |
|
|
(66,720 |
) |
|
|
(69,949 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock deemed dividend |
|
|
(8,469 |
) |
|
|
-- |
|
|
|
(8,469 |
) |
|
|
-- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss allocable to common stockholders |
|
$ |
(21,525 |
) |
|
$ |
(20,543 |
) |
|
$ |
(75,189 |
) |
|
$ |
(69,949 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share allocable to
common stockholders |
|
$ |
(0.09 |
) |
|
$ |
(0.11 |
) |
|
$ |
(0.38 |
) |
|
$ |
(0.41 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used to compute basic and diluted net loss per
share allocable to common stockholders |
|
|
235,879 |
|
|
|
180,685 |
|
|
|
196,275 |
|
|
|
170,469 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DYNAVAX TECHNOLOGIES CORPORATION |
SELECTED BALANCE SHEET DATA |
(In thousands) |
(Unaudited) |
|
|
|
December 31, |
|
December 31, |
|
|
2013 |
|
2012 |
Assets |
|
|
|
|
|
|
|
Cash,
cash equivalents and marketable securities |
|
$ |
189,376 |
|
$ |
125,130 |
|
Property and equipment, net |
|
|
8,706 |
|
|
7,965 |
|
Goodwill |
|
|
2,579 |
|
|
2,475 |
|
Other
assets |
|
|
3,961 |
|
|
4,182 |
Total assets |
|
$ |
204,622 |
|
$ |
139,752 |
|
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
|
Deferred revenues |
|
$ |
7,298 |
|
$ |
12,068 |
|
Other
liabilities |
|
|
11,030 |
|
|
12,858 |
|
Total
liabilities |
|
|
18,328 |
|
|
24,926 |
|
Stockholders' equity |
|
|
186,294 |
|
|
114,826 |
Total liabilities and stockholders' equity |
|
$ |
204,622 |
|
$ |
139,752 |
|
|
|
|
|
|
|
Contact: Michael Ostrach Chief Business and Principal Financial
Officer 510-665-7257 Email Contact
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024